Neuropathy & Pain

GW Pharmaceuticals announced preliminary results of two Phase III studies of Sativex®, its cannabinoid spray medicine, in peripheral neuropathic pain.

C-peptide improves sensory nerve function in type 1 diabetic patients with early-stage diabetic neuropathy.

Duloxetine was linked with modest changes in glycemia in patients with diabetic peripheral neuropathic pain (DPNP), according to the results of 3 randomized trials.

Acording to a report in the November issue of Diabetes Care, Alpha-lipoic acid (ALA) given orally improves symptoms in patients with diabetic polyneuropathy.

Tall people, regardless of whether they have diabetes or not, are at increased risk for peripheral insensate neuropathy.

A portable, automated device accurately detects electrophysiological abnormalities in the sural nerve, indicating diabetic sensorimotor polyneuropathy,

Neuropathies occur in much earlier stages of abnormal glucose metabolism than previously thought.